Recurrent ovarian cancers respond to cancer vaccine after “reprogramming” with decitabine

Recurrent ovarian cancers respond to cancer vaccine after “reprogramming” with decitabine Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with this disease, according to a Roswell Park … Continue reading “Recurrent ovarian cancers respond to cancer vaccine after “reprogramming” with decitabine”

Recurrent ovarian cancers respond to cancer vaccine after “reprogramming” with decitabine

Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with this disease, according to a Roswell Park Cancer Institute study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

Click here to read the full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply